Seattle Genetics, Inc. $600 Million Equity Offering

Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with an SEC-registered offering by Seattle Genetics, Inc. of 13,269,230 shares of common stock, which includes 1,730,769 shares of common stock sold pursuant to the exercise of the underwriters’ over-allotment option.

Seattle Genetics is a biotechnology company focused on the development and commercialization of targeted therapies for the treatment of cancer.

The Davis Polk corporate team included partner Alan F. Denenberg, counsel Jason Bassetti and associates Xin (Anita) Guo, Benson Richards and Lucas Tejwani. Partner Rachel D. Kleinberg and associate Caroline E. Dayton provided tax advice. Counsel Michelle Ontiveros Gross and associate Jason J. Bang provided intellectual property and technology advice. Members of the Davis Polk team are based in the Northern California and New York offices.